The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Concurrent chemoradiation followed by durvalumab yields objective responses in only ~30% of stage III unresectable NSCLC, while toxicity and normal-tissue constraints preclude meaningful radiation ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after ...

CHICAGO -- Adding perioperative durvalumab (Imfinzi) to FLOT chemotherapy significantly improved event-free survival (EFS) compared with FLOT alone in patients with resectable gastric or ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy as ...

Intratumoral delivery emerged to overcome suboptimal systemic immunotherapy response rates in “hot” tumors where escalating systemic dosing is constrained by toxicity. Standardization challenges span ...

Adding the immune checkpoint inhibitor durvalumab (Imfinzi) to the standard chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) improved event-free survival (EFS) in ...

BERLIN -- In a global phase III trial, the addition of durvalumab (Imfinzi) to standard chemotherapy given before and after surgery led to a statistically significant and "clinically meaningful" ...

IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer Based on POTOMAC Phase III trial results ...